Celebrity Cancers Stoking Fear? Cisplatin Shortage Ends; Setback for Anti-TIGIT

Are celebrity cancer diagnoses heightening cancer fears? (Washington Post)

In related news, the rock band Heart postponed its tour after lead singer Ann Wilson underwent surgery to remove a malignant tumor. (CNN)

A new artificial intelligence tool can help physicians determine how a patient will respond to cancer therapies across multiple types of cancer. (Nature Cancer)

FDA Commissioner Robert Califf, MD, announced that cisplatin is no longer in short supply. (Fierce Pharma)

Surveillance of individuals with a genetic or familial predisposition to pancreatic cancer may lead to the detection of smaller, lower-stage tumors and improve survival. (JAMA Oncology)

The phase III CARTITUDE-4 study of lenalidomide (Revlimid)-refractory multiple myeloma showed that ciltacabtagene autoleucel (Carvykti) improved overall survival versus either pomalidomide (Pomalyst), bortezomib (Velcade), and dexamethasone, or daratumumab (Darzalex), pomalidomide, and dexamethasone, Legend Biotech announced.

A federal judge dismissed a lawsuit brought by a Johnson & Johnson subsidiary against a scientist who published a paper linking talc products to cancer. The judge determined the research was neither fraudulent nor libelous. (Reuters)

Cancer patients should stick to science-backed medicine and avoid quack diets, the author of an opinion piece argued in Scientific American.

V. Craig Jordan, PhD, a pharmacologist who discovered that tamoxifen — a failed contraceptive — could block the growth of breast cancer cells, died at age 76. (New York Times)

Adding the investigational TIGIT inhibitor tiragolumab to first-line atezolizumab (Tecentriq) plus chemotherapy for metastatic non-squamous non-small cell lung cancer did not improve survival outcomes versus pembrolizumab (Keytruda) plus chemotherapy in the SKYSCRAPER-06 trial, Roche announced; the company said it will discontinue the phase II/III study.

A Texas woman with sickle cell disease celebrated her 80th birthday; patients with the disease have an average life expectancy of 52 years. (NBC News)

Tracon Pharmaceuticals said it will terminate development of envafolimab for advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma after the pivotal ENVASARC trial failed to meet its primary endpoint.

Please enable JavaScript to view the

comments powered by Disqus.